Filtered By:
Source: International Journal of Oncology
This page shows you your search results in order of date.
Order by Relevance | Date
Total 198 results found since Jan 2013.
P2Y < sub > 2 < /sub > R ‑mediated transactivation of VEGFR2 through Src phosphorylation is associated with ESM‑1 overexpression in radiotherapy‑resistant‑triple negative breast cancer cells
Int J Oncol. 2023 Jun;62(6):73. doi: 10.3892/ijo.2023.5521. Epub 2023 May 11.ABSTRACTWe previously reported that radiotherapy‑resistant (RT‑R) triple negative breast cancer (TNBC) cells upregulate the expression of endothelial‑specific molecule‑1 (ESM‑1) compared with TNBC cells. In addition, ESM‑1 is involved in an increased proliferation and invasion of RT‑R‑TNBC cells compared with TNBC cells. It was further identified that, in RT‑R‑TNBC cells, P2Y2 purinergic receptor (P2Y2R)‑mediated activation of p21‑activated kinase 1 (PAK1), protein kinase C (PKC), c‑Jun N‑terminal kinase (JNK) and p38 M...
Source: International Journal of Oncology - May 11, 2023 Category: Cancer & Oncology Authors: Hana Jin Young Shin Ko Seung Pil Yun Sang Won Park Hye Jung Kim Source Type: research
BST2 regulated by the transcription factor STAT1 can promote metastasis, invasion and proliferation of oral squamous cell carcinoma via the AKT/ERK1/2 signaling pathway
Int J Oncol. 2023 Apr;62(4):54. doi: 10.3892/ijo.2023.5502. Epub 2023 Mar 17.ABSTRACTOral squamous cell carcinoma (OSCC) is one of the main types of head and neck squamous cell carcinoma. Although progress has been made in treating OSCC, it remains a threat to human health, and novel therapeutic strategies are needed to extend the lifespan of patients with OSCC. The present study, evaluated whether bone marrow stromal antigen 2 (BST2) and STAT1 were potential therapeutic targets in OSCC. Small interfering RNA (siRNA) or overexpression plasmids were used to regulate BST2 or STAT1 expression. Western blotting and reverse tra...
Source: International Journal of Oncology - March 17, 2023 Category: Cancer & Oncology Authors: Fayu Shan Si Shen Xinxing Wang Gang Chen Source Type: research
Gefitinib enhances the anti ‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H
Int J Oncol. 2022 Dec;61(6):146. doi: 10.3892/ijo.2022.5436. Epub 2022 Oct 7.ABSTRACTGefitinib is a sensitive and effective drug to treat non‑small‑cell lung cancer (NSCLC) carrying the somatic activating mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR). In the present study, a new mechanism of action of gefitinib in EGFR‑mutated NSCLC cells was discovered using in vitro co‑culture of NSCLC cells with peripheral blood mononuclear cells (PBMCs). Gefitinib significantly enhanced the cytotoxicity of PBMCs against NSCLC cells expressing mutated EGFR but not in cells expressing wild‑t...
Source: International Journal of Oncology - October 7, 2022 Category: Cancer & Oncology Authors: Huihui Guo Xilin Zhang Shangzhi Xie Tianwei Chen Dong Xie Ying Cai Dawei Cui Liang Wang Wei Chen Xiang Wang Source Type: research
